Page 129 - Demo

Parkinson’s disease in 22q11.2DS127319. Boulos C, Yaghi N, El Hayeck R, Heraoui GN, Fakhoury-Sayegh N. Nutritional Risk Factors, Microbiota and Parkinson’s Disease: What Is the Current Evidence? Nutrients. Aug 14 2019;11(8)doi:10.3390/nu1108189620. Giladi N, Mirelman A, Thaler A, Bar-Shira A, Gurevich T, Orr-Urtreger A. Fighting the risk of developing Parkinson’s disease; clinical counseling for first degree relatives of patients withParkinson’s disease. J Neurol Sci. Nov 15 2011;310(1-2):17-20. doi:10.1016/j.jns.2011.06.00521. Mulhern M, Bier L, Alcalay RN, Balwani M. Patients’ Opinions on Genetic Counseling on the Increased Risk of Parkinson Disease among Gaucher Disease Carriers. J Genet Couns. Jun 2018;27(3):675-680. doi:10.1007/s10897-017-0161-022. Tsou AY, Bulova P, Capone G, et al. Medical Care of Adults With Down Syndrome: A Clinical Guideline. JAMA. 2020;324(15):1543-1556. doi:10.1001/jama.2020.1702423. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. Mar 23 2017;3:17013. doi:10.1038/nrdp.2017.1324. Moberg PJ, Turetsky BI, Moberg EA, et al. Meta-analysis of olfactory dysfunction in 22q11.2 deletion syndrome. Psychiatry Res. Jan 16 2020;285:112783. doi:10.1016/j.psychres.2020.11278325. Bassett AS, Chow EW, Husted J, et al. Clinical features of 78 adults with 22q11 Deletion Syndrome. Am J Med Genet A. Nov 1 2005;138(4):307-13. doi:10.1002/ajmg.a.3098426. Buckley E, Siddique A, McNeill A. Hyposmia, symptoms of rapid eye movement sleep behavior disorder, and parkinsonian motor signs suggest prodromal neurodegeneration in 22q11 deletion syndrome. Neuroreport. Aug 2 2017;28(11):677-681. doi:10.1097/wnr.000000000000081527. Mauro J, Diaz M, Córdova T, et al. Analysis of REM sleep without atonia in 22q11.2 deletion syndrome determined by domiciliary polysomnography: a cross sectional study. Sleep. 2022;45(2):zsab300. doi:10.1093/sleep/zsab30028. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, andheritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. The Lancet Neurology. 2019/12/01/ 2019;18(12):1091-1102. doi:https://doi.org/10.1016/S1474-4422(19)30320-529. Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson’s disease. Lancet Neurol. Feb 2020;19(2):170-178. doi:10.1016/s1474-4422(19)30287-x30. Ross OA, Braithwaite AT, Skipper LM, et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. Jun 2008;63(6):743-50. doi:10.1002/ana.2138031. von Scheibler E, van Eeghen AM, de Koning TJ, et al. Parkinsonism in Genetic Neurodevelopmental Disorders: A Systematic Review. Mov Disord Clin Pract. Jan 2023;10(1):17-31. doi:10.1002/mdc3.1357732. Chia SJ, Tan EK, Chao YX. Historical Perspective: Models of Parkinson’s Disease. Int J Mol Sci. Apr 2 2020;21(7)doi:10.3390/ijms2107246433. Sumitomo A, Horike K, Hirai K, et al. A mouse model of 22q11.2 deletions: Molecular and behavioral signatures of Parkinson’s disease and schizophrenia. Sci Adv. Aug 2018;4(8):eaar6637. doi:10.1126/sciadv.aar663734. Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The Incidence of Parkinson’s Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2016;46(4):292-300. doi:10.1159/000445751